An integrated assessment tool to define effective air quality policies at regional scale

In this paper, the Integrated Assessment of air quality is dealt with at regional scale. First the paper describes the main challenges to tackle current air pollution control, including economic aspects. Then it proposes a novel approach to manage the problem, presenting its mathematical formalization and describing its practical implementation into the Regional Integrated Assessment Tool (RIAT). The main features of the software system are described and some preliminary results on a domain in Northern Italy are illustrated. The novel features in RIAT are then compared to the state-of-the-art in integrated assessment of air quality, for example the ability to handle nonlinearities (instead of the usual linear approach) and the multi-objective framework (alternative to cost-effectiveness and scenario analysis). Then the lessons learned during the RIAT implementation are discussed, focusing on the locality, flexibility and openness of the tool. Finally the areas for further development of air quality integrated assessment are highlighted, with a focus on sensitivity analysis, structural and non technical measures, and the application of parallel computing concepts

A TOOL TO SUPPORT EMISSION REDUCTION PLANNING AT REGIONAL SCALE

Tropospheric pollutants originate from complex chemical reactions and physical processes involving precursor emissions, namely VOC, NOx, NH3, primary PM and SO2. Decision makers should thus develop reduction plans of precursors emissions to fulfil national and international commitments, such as EU directive 2008/50, minimizing the implementation costs of such plans. The paper presents the design of the Regional Integrated Assessment Tool (RIAT), a Decision Support System implementing a multi-objective methodology for Air Quality planning

N-3 fatty acids in patients with multiple cardiovascular risk factors

BACKGROUND: Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS: In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS: Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS: In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. Copyright © 2013 Massachusetts Medical Society